Studies on a series of potent, orally bioavailable, 5-HT1 receptor ligands—Part II
作者:Simon E. Ward、Peter Eddershaw、Sean T. Flynn、Laurie Gordon、Peter J. Lovell、Susan H. Moore、Claire M. Scott、Paul W. Smith、Kevin M. Thewlis、Paul A. Wyman
DOI:10.1016/j.bmcl.2008.11.052
日期:2009.1
A series of 5-(piperidinylethyloxy)quinoline 5-HT1 receptor ligands have been studied by elaboration of the series of dual 5-HT1-SSRIs reported previously. These new compounds display a different in vitro pharmacological profile with potent affinity across the 5-HT1A, 5-HT1B and 5-HT1D receptors and selectivity against the serotonin transporter. Furthermore, they have improved pharmacokinetic profiles
通过阐述先前报道的一系列双5-HT 1 -SSRI,已经研究了一系列5-(哌啶基乙氧基)喹啉5-HT 1受体配体。这些新化合物显示出不同的体外药理学特征,对5-HT 1A,5-HT 1B和5-HT 1D受体具有强大的亲和力,并且对5-羟色胺转运蛋白具有选择性。此外,它们具有改善的药代动力学特征和中枢神经系统渗透性。